DÃaz-Tejeiro, C.; López de Sá, A.; Poyatos-Racionero, E.; BallestÃn, P.; Bartolomé, J.; Calvo, E.; Moreno, V.; Moris, F.; Pérez-Segura, P.; Gyorffy, B.;
et al. Understanding the Preclinical Efficacy of Antibody–Drug Conjugates. Int. J. Mol. Sci. 2024, 25, 12875.
https://doi.org/10.3390/ijms252312875
AMA Style
DÃaz-Tejeiro C, López de Sá A, Poyatos-Racionero E, BallestÃn P, Bartolomé J, Calvo E, Moreno V, Moris F, Pérez-Segura P, Gyorffy B,
et al. Understanding the Preclinical Efficacy of Antibody–Drug Conjugates. International Journal of Molecular Sciences. 2024; 25(23):12875.
https://doi.org/10.3390/ijms252312875
Chicago/Turabian Style
DÃaz-Tejeiro, Cristina, Alfonso López de Sá, Elisa Poyatos-Racionero, Pablo BallestÃn, Jorge Bartolomé, Emiliano Calvo, VÃctor Moreno, Francisco Moris, Pedro Pérez-Segura, Balazs Gyorffy,
and et al. 2024. "Understanding the Preclinical Efficacy of Antibody–Drug Conjugates" International Journal of Molecular Sciences 25, no. 23: 12875.
https://doi.org/10.3390/ijms252312875
APA Style
DÃaz-Tejeiro, C., López de Sá, A., Poyatos-Racionero, E., BallestÃn, P., Bartolomé, J., Calvo, E., Moreno, V., Moris, F., Pérez-Segura, P., Gyorffy, B., Pandiella, A., & Ocaña, A.
(2024). Understanding the Preclinical Efficacy of Antibody–Drug Conjugates. International Journal of Molecular Sciences, 25(23), 12875.
https://doi.org/10.3390/ijms252312875